TLR2 and neoplasm: In the B16.F10 mouse melanoma model, the TLR2 agonist Pam3CSK4 induced MCs to release cytokines such as IL-6 and CCL3, which mediated a direct antiproliferative effect on tumor cells and the recruitment of NK and T cells, respectively [36].